glp1guide

Taxpayers already are -- see: https://news.ycombinator.com/item?id=39350390

> Already, seniors make up 26.6 percent of the people who have been prescribed these and other GLP-1 agonists, including Ozempic, since 2018, according to a report from Truveta, which draws data from a large network of health-care systems.

> In the coming years, that proportion could rise even higher: The bipartisan Treat and Reduce Obesity Act, introduced in Congress last July, would allow Medicare to cover drug treatments for obesity among its roughly 50 million Part D enrollees above the age of 65; in principle, about two-fifths of that number would qualify as patients.

I did not know this and was pretty shocked. Of course I don't object to it, but didn't know this had happened already.

Also, the WHO is possibly going to put Liraglutide (Victoza/Saxenda) on the Essential Medicines List[0].

[0]: https://glp1.guide/content/the-who-might-add

Appreciate the links, going to dig in -- thank you!

Ah small correction here: Ozempic isn't insulin -- it's a GLP1 Receptor Agonist[0]. While the companies that make these kinds of drugs do make Insulin (for example IIRC that's now Novo Nordisk got it's start), that's not what the drugs actually are.

[0]: https://glp1.guide/content/what-are-glp1-agonists

Yeah, appetite suppressants can only do so much, and if you don't change your eating habits/what you buy while you're on the drug, it seems that many people regain weight quite fast when off of it.

That said, studies on weight regain have shown that most people actually don't gain all the weight they lost back. That's quite miraculous compared to the difficulty of pure strength-of-will based approaches.

> Already, seniors make up 26.6 percent of the people who have been prescribed these and other GLP-1 agonists, including Ozempic, since 2018, according to a report from Truveta, which draws data from a large network of health-care systems.

> In the coming years, that proportion could rise even higher: The bipartisan Treat and Reduce Obesity Act, introduced in Congress last July, would allow Medicare to cover drug treatments for obesity among its roughly 50 million Part D enrollees above the age of 65; in principle, about two-fifths of that number would qualify as patients.

TIL, this is a big change that went mostly under the radar (well, my radar at least!).

I have a sneaking suspicion though that once availability goes up and price goes down, we'll see many more than seniors on the drugs.

Sorry if this is a silly question, but goes GLP-1 gene therapy exist yet? I've been doing a ton of fact findin on GLP-1 recently and absolutely have not come across this.

The thing is, there's the main ingredients (semaglutide/liraglutide/exenatide/tirzepatide/...) and also the ingestion mechanism -- like Rybelsus can be taken orally and has a MUCH lower dosage/absorption rate. Only some of them seem to have "extra" side effects (the scariest of which being suicidal thoughts).